Literature DB >> 25346064

Frontostriatal dysexecutive syndrome: a core cognitive feature of myotonic dystrophy type 2.

Stojan Peric1, Gorana Mandic-Stojmenovic, Elka Stefanova, Dusanka Savic-Pavicevic, Jovan Pesovic, Vera Ilic, Valerija Dobricic, Ivana Basta, Dragana Lavrnic, Vidosava Rakocevic-Stojanovic.   

Abstract

The aim of this study was to assess cognitive status in a large group of patients with myotonic dystrophy type 2 (DM2) compared to type 1 (DM1) subjects matched for gender and age, using a comprehensive battery of neuropsychological tests. Thirty-four genetically confirmed adult DM2 patients were recruited and matched for gender and age with 34 adult-onset DM1 subjects. All patients underwent detailed classic pen and pencil neuropsychological investigation and also computerized automated battery-CANTAB. More than half of DM2 patients had abnormal results on executive tests [Intra/Extradimensional Set Shift (IED), Stockings of Cambridge (SOC)] and verbal episodic memory (Ray Auditory Verbal Learning Test). Regarding DM1, abnormal results in more than 50 % of subjects were achieved in even ten tests, including visuospatial, language, executive, cognitive screening and visual memory tests. Direct comparison between patient groups showed that lower percentage of DM2 patients had abnormal results on following tests: Addenbrooke's Cognitive Examination-Revised, Raven Standard Progressive Matrices, Block Design, copy and recall of Rey-Osterieth Complex Figure, number of categories and perseverative responses on Wisconsin Card Sorting Test and Boston Naming Test (p < 0.01), as well as Trail Making Test-B and Spatial Span (p < 0.05). Our results showed significant dysexecutive syndrome and certain impairment of episodic verbal memory in DM2 patients that are reflective of frontal (especially frontostriatal) and temporal lobe dysfunction. On the other hand, dysexecutive and visuospatial/visuoconstructional deficits predominate in DM1 which correspond to the frontal, parietal (and occipital) lobe dysfunction.

Entities:  

Mesh:

Year:  2014        PMID: 25346064     DOI: 10.1007/s00415-014-7545-y

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  35 in total

1.  Cerebral and muscle MRI abnormalities in myotonic dystrophy.

Authors:  Daniel T Franc; Ryan L Muetzel; Paul R Robinson; Craig P Rodriguez; Joline C Dalton; Cameron E Naughton; Bryon A Mueller; Jeffrey R Wozniak; Kelvin O Lim; John W Day
Journal:  Neuromuscul Disord       Date:  2012-01-30       Impact factor: 4.296

2.  Intracytoplasmic inclusion bodies of the thalamus and the substantia nigra, and Marinesco bodies in myotonic dystrophy: a quantitative morphological study.

Authors:  S Ono; K Inoue; T Mannen; S Mitake; T Shirai; F Kanda; K Jinnai; K Takahashi
Journal:  Acta Neuropathol       Date:  1989       Impact factor: 17.088

3.  Loss of serotonin-containing neurons in the raphe of patients with myotonic dystrophy: a quantitative immunohistochemical study and relation to hypersomnia.

Authors:  S Ono; K Takahashi; K Jinnai; F Kanda; Y Fukuoka; H Kurisaki; S Mitake; T Inagaki; T Yamano; K Nagao
Journal:  Neurology       Date:  1998-02       Impact factor: 9.910

4.  Reduced cerebral blood flow and impaired visual-spatial function in proximal myotonic myopathy.

Authors:  G Meola; V Sansone; D Perani; A Colleluori; S Cappa; M Cotelli; F Fazio; C A Thornton; R T Moxley
Journal:  Neurology       Date:  1999-09-22       Impact factor: 9.910

5.  Assessment of a disease-specific muscular impairment rating scale in myotonic dystrophy.

Authors:  J Mathieu; H Boivin; D Meunier; M Gaudreault; P Bégin
Journal:  Neurology       Date:  2001-02-13       Impact factor: 9.910

6.  Subtle cognitive dysfunction in adult onset myotonic dystrophy type 1 (DM1) and type 2 (DM2).

Authors:  C Gaul; T Schmidt; G Windisch; T Wieser; T Müller; S Vielhaber; S Zierz; B Leplow
Journal:  Neurology       Date:  2006-07-25       Impact factor: 9.910

7.  Clinically probable multiple system atrophy with predominant parkinsonism associated with myotonic dystrophy type 2.

Authors:  Shen-Yang Lim; Pettarusp Wadia; Gregor K Wenning; Anthony E Lang
Journal:  Mov Disord       Date:  2009-07-15       Impact factor: 10.338

8.  Executive dysfunction and avoidant personality trait in myotonic dystrophy type 1 (DM-1) and in proximal myotonic myopathy (PROMM/DM-2).

Authors:  G Meola; V Sansone; D Perani; S Scarone; S Cappa; C Dragoni; E Cattaneo; M Cotelli; C Gobbo; F Fazio; G Siciliano; M Mancuso; E Vitelli; S Zhang; R Krahe; R T Moxley
Journal:  Neuromuscul Disord       Date:  2003-12       Impact factor: 4.296

9.  Early dopasensitive Parkinsonism related to myotonic dystrophy type 2.

Authors:  Agnès Annic; David Devos; Alain Destée; Luc Defebvre; Arnaud Lacour; Jean-François Hurtevent; Tanya Stojkovic
Journal:  Mov Disord       Date:  2008-10-30       Impact factor: 10.338

10.  Quantification of brain atrophy in patients with myotonic dystrophy and proximal myotonic myopathy: a controlled 3-dimensional magnetic resonance imaging study.

Authors:  Jan Kassubek; Freimut D Juengling; Stefanie Hoffmann; Angela Rosenbohm; Anja Kurt; Karin Jurkat-Rott; Peter Steinbach; Michael Wolf; Albert C Ludolph; Frank Lehmann-Horn; Holger Lerche; Yvonne G Weber
Journal:  Neurosci Lett       Date:  2003-09-11       Impact factor: 3.046

View more
  17 in total

Review 1.  Myotonic dystrophy type 2 and modifier genes: an update on clinical and pathomolecular aspects.

Authors:  Giovanni Meola; Rosanna Cardani
Journal:  Neurol Sci       Date:  2017-01-11       Impact factor: 3.307

2.  Magnetic resonance imaging of leg muscles in patients with myotonic dystrophies.

Authors:  Stojan Peric; Ruzica Maksimovic; Bojan Banko; Milica Durdic; Bogdan Bjelica; Ivo Bozovic; Yunus Balcik; Jovan Pesovic; Dusanka Savic-Pavicevic; Vidosava Rakocevic-Stojanovic
Journal:  J Neurol       Date:  2017-07-29       Impact factor: 4.849

3.  Clusters of cognitive impairment among different phenotypes of myotonic dystrophy type 1 and type 2.

Authors:  Stojan Peric; Vidosava Rakocevic Stojanovic; Gorana Mandic Stojmenovic; Vera Ilic; Masa Kovacevic; Aleksandra Parojcic; Jovan Pesovic; Milija Mijajlovic; Dusanka Savic-Pavicevic; Giovanni Meola
Journal:  Neurol Sci       Date:  2016-11-28       Impact factor: 3.307

4.  Molecular genetic and clinical characterization of myotonic dystrophy type 1 patients carrying variant repeats within DMPK expansions.

Authors:  Jovan Pešović; S Perić; M Brkušanin; G Brajušković; V Rakočević-Stojanović; Dušanka Savić-Pavićević
Journal:  Neurogenetics       Date:  2017-09-23       Impact factor: 2.660

Review 5.  Biomolecular diagnosis of myotonic dystrophy type 2: a challenging approach.

Authors:  Giovanni Meola; Fiammetta Biasini; Rea Valaperta; Elena Costa; Rosanna Cardani
Journal:  J Neurol       Date:  2017-05-26       Impact factor: 4.849

6.  Cortical and Subcortical Grey and White Matter Atrophy in Myotonic Dystrophies Type 1 and 2 Is Associated with Cognitive Impairment, Depression and Daytime Sleepiness.

Authors:  Christiane Schneider-Gold; Barabara Bellenberg; Christian Prehn; Christos Krogias; Ruth Schneider; Jan Klein; Ralf Gold; Carsten Lukas
Journal:  PLoS One       Date:  2015-06-26       Impact factor: 3.240

7.  Myotonic Dystrophy Type 2: An Update on Clinical Aspects, Genetic and Pathomolecular Mechanism.

Authors:  Giovanni Meola; Rosanna Cardani
Journal:  J Neuromuscul Dis       Date:  2015-07-22

8.  Personality traits in patients with myotonic dystrophy type 2.

Authors:  Teodora Paunic; Stojan Peric; Aleksandra Parojcic; Dusanka Savic-Pavicevic; Milorad Vujnic; Jovan Pesovic; Ivana Basta; Dragana Lavrnic; Vidosava Rakocevic-Stojanovic
Journal:  Acta Myol       Date:  2017-03

Review 9.  Myotonic disorders: A review article.

Authors:  Chris Hahn; Mohammad Kian Salajegheh
Journal:  Iran J Neurol       Date:  2016-01-05

10.  Multidimensional aspects of pain in myotonic dystrophies.

Authors:  Marina Peric; Stojan Peric; Nada Rapajic; Valerija Dobricic; Dusanka Savic-Pavicevic; Ivana Nesic; Svetlana Radojicic; Ivana Novakovic; Dragana Lavrnic; Vidosava Rakocevic-Stojanovic
Journal:  Acta Myol       Date:  2015-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.